

November 14, 2019

The General Manager
Corporate Relation Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai-400001

Dear Sir,

Sub.: Outcome of the Meeting of Board of Directors held today i.e. November 14, 2019.

Ref.: Scrip code - 539680

With reference to the captioned subject and in compliance with the regulation 30 and other applicable regulation of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. Thursday, November 14, 2019 at 12:00 noon and concluded at 1.00 p.m. inter-alia have; the following:



1. Considered and approved the un-audited financial results of the Company for the half year ended on September 30, 2019.

A copy of the Un-audited Financial Results for the half year ended on September 30, 2019 as adopted and approved by the Board of Directors together with the limited review report of the Auditors thereon is attached herewith.

Please take the same on your record and suitably disseminated at all concerned.

Thanking you,

Yours faithfully,
For Ganga Pharmaceuticals Limited



Bharat Sharma
Managing Director
DIN: 00077026
Email id: bharat.sharma@gangapharma.in

Regd. Office & Factory : Gangatat, Dhanvantri Marg, Gopchar Pada, Virar (E), 401 305, (Mumbai) INDIA

Tel. : 84520 49222 / 99678 40111

e-mail : gplvirar@gmail.com / gangapharmaltd@gmail.com • Website : www.ayurvedganga.com

CIN No. : L99999MH1989PLC053392

GST No. : 27AABCG3922H1ZS



Anil Bansal & Associates

CHARTERED ACCOUNTANT

1001, IJMIMA Complex,
Raheja's Metroplex,
Near Infinity Mall-II,
Link Road, Malad (West),
Mumbai - 400064.
Phone : 67098000/01
e-mail : anilbansal1001@gmail.com

INDEPENDENT AUDITORS LIMITED REVIEW REPORT ON UNAUDITED FINANCIAL RESULTS OF THE COMPANY FOR THE HALF YEAR ENDED 30.09.2019 PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED)

To
The Board of Director
Ganga Pharmaceuticals Ltd

We have reviewed the accompanying statement of unaudited financial results of **Ganga Pharmaceuticals Ltd** for the period ended on 30th September, 2019. This Statement is the responsibility of the Company's Management and has been approved by the Board of Director. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (RE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any materials misstatement.

For: Anil Bansal & Associates
Chartered Accountants
Firm Registration No. 100421W

Anil Bansal
Proprietor

Membership Number 043918

UDIN: 19043918 A AAAA 1506881

Place: Mumbai

Date: 14th November, 2019



GANGA PHARMACEUTICALS LIMITED

CIN: L99999MH1989PLC053392

REGISTERED OFFICE ADDRESS : GANGATAT, DHANVANTARI MARG, GOPCHAR PADA, VIRAR (EAST)-401305

Tele No.+91-250-6098444 Email id: gangapharmaltd@gmail.com , Website: www.ayurvedganga.com

Statement of Unaudited Financial Result for the Half Year Ended on 30th September,2019

Sr. No	Particulars	Half year ended on			(Rs.In Lakhs)
		30-09-2019	31-03-2019	30-09-2018	Year ended on
		(Un-Audited)	(Un-Audited)	(Un-Audited)	(Audited)
1	INCOME FROM OPERATIONS				
	(a) Revenue from operations	138.24	159.74	176.52	336.26
	(b) Other Income	7.50	7.47	6.92	14.39
	Total Income	145.74	167.21	183.44	350.65
2	Expenses:				
	(a) Cost of Materials consumed	64.20	35.77	88.80	124.57
	(b) Purchase of stock in trade			-	-
	(c) Change in inventories of finished, WIP and stock in trade	3.12	22.55	(23.73)	(1.17)
	(d) Employee Benefit Expenses	14.28	21.58	22.94	44.52
	(e) Finance Cost	12.18	12.84	12.29	25.13
	(f) Depreciation and Amortization Expense	2.60	1.53	3.76	5.29
	(g) Other Administrative Expenses	28.37	67.13	59.34	126.47
	Total Expenses	124.75	161.40	163.40	324.80
3	Profit/(Loss) before Tax (1-2)	20.98	5.81	20.04	25.85
4	Tax Expenses				
	(a) Current Tax	5.29	1.47	5.16	6.63
=	(b) Deffered Tax	0.16	0.50	0.00	0.50
5	Net Profit / (Loss) for the period (3-4)	15.53	3.84	14.88	18.71
6	Other Comprehensive Income		-	-	-
7	Paid - Up equity share capital (Equity Share of Rs. 10/- each)	406.15	406.15	406.15	406.15
8	Earning per equity share (Rs.)				
	(1) Basic	0.04	0.09	0.37	0.46
	(2) Diluted	0.04	0.09	0.37	0.46

For and on behalf of the Board of Directors of
Ganga Pharmaceuticals Limited


Bharat Sharma

Managing Director

DIN : 00077026

Place: Virar (Palghar)

Date : 14 November, 2019



Notes:

1. The above said financial results were reviewed by the Audit Committee and then approved by the board of directors at their respective Meeting held on 14th November, 2019.
2. The statutory Auditors have carried out limited review of the unaudited results of the company for the half year ended 30.09.2019.
3. The statement is prepared in accordance with the requirement of Accounting Standards (AS) specified under section 133 of the companies Act, 2013 read with the rule 7 of the companies (Accounts) Rules, 2014.
4. As per MCA Notification dated 16th February, 2015 companies whose share are listed on SME exchange as referred to in chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulation, 2009, are exempted from the compulsory requirement of adoption of IND-AS.
5. Earnings per Share: Earnings per share is calculated on the weighted average of the share capital received by the company. Half Yearly EPS is not annualized.
6. Previous year/ period figures have been re-grouped, re-arranged wherever considered necessary.
7. The company is not having any subsidiary, associate or joint venture, therefore, it has prepared only standalone results.
8. All activities of the company revolve around the main business and as such there is no separate reportable business segment and all the operations of the company are conducted within India as such there is no separate reportable geographical segment.
9. Statement of assets and liabilities as on 30th September, 2019 is enclosed herewith:

For Ganga Pharmaceuticals Limited


Bharat Sharma

Managing Director

DIN: 00077026



GANGA PHARMACEUTICALS LTD

CIN: L99999MH1989PLC053392

Registered Office: Gangatat, Dhanvantari Marg, Gopcharpada, Virar (East), Palghar -401305

Tele Nos.:0250-6098333/444 ; Website: www.ayurvedganga.com; Email id:gangapharmaltd@gmail.com

Statement of Assests and Liabilities as at 30th September 2019

(Rs.In Lakhs)

	Statement of Assets and Liabilities Particulars	Half Year Ended on (Unaudited) 30-09-2019	Year Ended on (Audited) 31-03-2019
I	EQUITY AND LIABILITIES		
	(1) Shareholders Funds:		
	(a) Share Capital	406.15	406.15
	(b) Reserve & Surplus	130.02	109.21
	(2) Non-Current Liabilities		
	(a) Long-Term Borrowings	63.54	66.23
	(b) Deferred Tax Liabilities (Net)	0.43	0.26
	(c) Other Long Term Liabilities	-	-
	(d) Long Term Provisions	-	-
	(3) Current Liabilities		
	(a) Short-term borrowings	116.77	121.07
	(b) Trade payables	53.04	54.82
	(c) Other current liabilities	14.25	17.62
	(d) Short-term provisions	0.43	0.43
	Total Equity and Liabilities	784.63	775.79
II	ASSETS		
	(1) Non - Current assets		
	(a) Fixed Assets	78.22	80.19
	(b) Non-current investments	8.93	8.93
	(c) Deferred tax assets (net)	-	-
	(d) Long term loans and advances	-	-
	(e) Other Non-current assets	278.70	251.69
	(2) Current assets		
	(a) Current Investment	-	-
	(b) Inventories	112.26	115.38
	(c) Trade receivables	110.03	122.64
	(d) Cash and cash equivalents	18.10	23.65
	(e) Short-term loans and advances	123.66	121.93
	(f) Other current assets	54.75	51.38
	Total Assets	784.63	775.79

For and on behalf of the Board of Directors of
Ganga Pharmaceuticals Limited

Bharat Sharma
Managing Director

DIN : 00077026

Place: Virar (Palghar)

Date : 14 November, 2019

